Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2008

01-02-2008

Reduction in emergency department visits by patients attending an anticoagulation clinic

Authors: P. Whittaker, J. L. Donovan, K. Przyklenk

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2008

Login to get access

Excerpt

Introduction Recent studies suggest that warfarin therapy may be linked to cardiac valve calcification. We aimed to establish whether calcification (C) of valves or other tissue occurs with warfarin and to examine if such C was influenced by treatment duration, age, or gender. Methods We performed a retrospective review of 50 long-term warfarin recipients and 50 untreated controls, matched for age, gender, and comorbidity. For inclusion, patients required a recent echocardiogram (within 18 months) and at least one CT-scan and X-ray. We determined a calcification score (CS) for each patient; one point per site was given for C reported in the aortic, mitral, or tricuspid valve, aorta, coronary and carotid arteries, peripheral vessels, kidney, lung, or other locations. Results The groups were matched for hypertension, diabetes, and coronary disease (P = NS); however, males were younger (64 ± 3 vs. 73 ± 2 years; P = 0.03). Most patients received warfarin for valve replacement (42%) or atrial fibrillation (36%); mean treatment duration, 99 ± 3 months. Analysis revealed five main results; (1) Warfarin-associated CS was increased in cardiac valves (P = 0.01 vs. control) and at each assessed site except the coronary arteries. (2) Total CS was higher with warfarin (2.7 ± 0.3) than controls (1.8 ± 0.2; P = 0.02). (3) CS correlated with warfarin treatment duration (P = 0.03). (4) When all patients were assessed, CS correlated with age for both groups, but was always higher with warfarin (P = 0.02 vs. control). (5) However, this effect was due to warfarin-induced C in males. Total CS was higher for warfarin-treated males (2.4 ± 0.4) versus controls (1.2 ± 0.2; P < 0.01), irrespective of age (P < 0.01). In contrast, we found no differences between warfarin-treated and control females. Conclusions Long-term warfarin therapy was associated with tissue calcification not only in valves, but also at other sites. For our entire warfarin-treated group, calcification correlated with treatment duration and age; however, the most pronounced increases occurred in males. …
Metadata
Title
Reduction in emergency department visits by patients attending an anticoagulation clinic
Authors
P. Whittaker
J. L. Donovan
K. Przyklenk
Publication date
01-02-2008
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2008
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0117-6

Other articles of this Issue 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.